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Abstract: Apoptosis is a common pathway that ﬁ  nally mediated the killing functions of 
anticancer drugs, which is an important cause of multidrug resistance (MDR). The aim of this 
study was to investigate the potential beneﬁ  t of combination therapy with magnetic nanoparticle 
of Fe3O4 (MNP(Fe3O4)) and 5-bromotetrandrin (BrTet). Analysis of the apoptosis percentage 
showed that combination of daunorubicin (DNR) with either MNP(Fe3O4) or BrTet exerted 
a potent cytotoxic effect on K562/A02 cells, while MNP(Fe3O4) and BrTet cotreatment can 
synergistically enhance DNR-induced apoptosis. Importantly, we conﬁ  rmed that the distinct 
synergism effect of that composite on reverse multidrug resistance may owe to the regulation 
of various proliferative and antiapoptotic gene products, including P53 and caspase-3. Thus 
our in vitro data strongly suggests a potential clinical application of MNP(Fe3O4) and BrTet 
combination on CML.
Keywords: K562/A02 leukemic cells, multidrug resistance, magnetic nanoparticle of Fe3O4, 
5-bromotetrandrine, apoptosis, P53, caspase-3
Introduction
The primary cause of treatment failures in leukemia is the emergence of multidrug 
resistance (MDR).1,2 Most chemotherapy agents are used in the treatment of hema-
tologic malignancies cells by inducing apoptosis; the resistance of leukemic cells to 
chemotherapy-induced apoptosis remains the most signiﬁ  cant problem in the treatment 
of leukemia.3,4 To reverse the resistance mechanism and reduce side effects during 
chemotherapy, a promising approach is to combine a conventional chemotherapy with 
new strategies inducing leukemia cell apoptosis. The possible solutions may include 
using drug delivery systems to enhance the related drug delivery efﬁ  ciency to cancer 
cells and chemosensitizers to inhibit ATP-binding cassette (ABC) transporters.5 
In order to achieve this goal, we chose the application of magnetic nanoparticle of 
Fe3O4 (MNP(Fe3O4)) and 5-bromotetrandrin (BrTet) to sensitize MDR cells in acute 
leukemia.
Traditional strategies towards the tissue-speciﬁ  c drug delivery utilize cytotoxic 
drugs attached to targeting moieties.6 Recently, many polymer nanospheres and 
nanoparticles have been introduced as drug delivery systems to enhance the related 
drug delivery efﬁ  ciency to cancer cells based on the ability to target speciﬁ  c loca-
tions in the body.7 Perhaps the most promising materials related to diagnosis and 
treatment of cancer are magnetic nanoparticles. Their magnetic properties enable these 
particles to be used in numerous applications8 such as being guided or held in place by 
means of a magnetic ﬁ  eld and heated in a magnetic ﬁ  eld to trigger drug release or to 
produce hyperthermia of tissue. Fe3O4 magnetic nanoparticles, a kind of biocompatible 
nanomaterial that is feasible to produce, characterize, and easily functionalize, are International Journal of Nanomedicine 2009:4 66
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widely used for targeted-drug carriers with target-orientation 
and sustained-release properties because of their chemical 
stability, low toxicity, and superparamagnetic qualities.9 
Some reports have demonstrated the synergistic effect of 
MNP(Fe3O4) with the anticancer drug daunorubicin (DNR) 
on the drug accumulation of leukemia cells.10 The diameter 
of MNP(Fe3O4) manufactured by Biological Science College 
of Southeast University is 20–30 nm, which is appropriate 
for reversal of MDR.11
Tetrandrine (Tet), a bisbenzylisoquinoline albaloid 
isolated from the Chinese herb “Hanfangji” (Stephania 
tetrandra Radix), holds great promise as a MDR modulator 
for the treatment of P-glycoprotein (P-gp)-mediated MDR 
cancers12 which have no apparent effect on doxorubicin 
pharmacokinetics in mice.13 Moreover, it is relatively well 
tolerated in these patients with poor risk acute myeloid 
leukemia (AML).14 5-Bromotetrandrine (BrTet), a bromized 
derivative of tetrandrine (Tet), shows more signiﬁ  cant MDR 
reversal activity in vitro and in vivo related to the inhibition 
of P-gp overexpression and the increase in intracellular 
accumulation of anticancer drugs.15,16
The present studies were undertaken to evaluate the 
ability of MNP(Fe3O4) and BrTet to sensitize MDR cells to 
anticancer agents in vitro and determine their combination 
effects on apoptosis induced by combining DNR in leukemic 
cells. Flow cytometry studies demonstrated that MNP(Fe3O4) 
and/or BrTet could enhance DNR-induced apoptosis in 
K562/A02 cells. Moreover, DNA gel electrophoresis 
revealed that the effects of MNP(Fe3O4) and BrTet combin-
ing with small dose chemotherapeutic agents were different 
from the effects of large dose chemotherapeutic agents on 
K562/A02 cells which induced necrosis. Importantly, by 
measuring the expressions of apoptosis-related gene and 
proteins, we found a distinct synergistic effect of that com-
posite on reverse MDR may owe to the regulation of various 
proliferative and antiapoptotic gene products, including P53 
and caspase-3, thus demonstrating the potential for using 
MNP(Fe3O4) and BrTet as a more sufﬁ  cient and less toxic 
anti-MDR method.
Materials and methods
Main reagents
Adriamycin (ADM; Hisun Phamaceutical Co., Zhejiang, 
China) and DNR (Main Luck Phamaceuticals Inc., 
Shenzheng, China) stock solution 2 mg/ml were prepared 
with 0.01 mol/l phosphate buffer saline (PBS) (PH 7.4). 
BrTet (Kanghong, Chengdou, China) was diluted with 0.01 
mol/l PBS (PH 7.4). Fe3O4 nanoparticles (State Key Lab of 
Bioelectronics, Chien-Shiung Wu Laboratory, Southeast 
University, Nanjing, China) were well distributed in 
RPMI 1640 medium (Gibco/BRL, Carlsbad, CA, USA) 
containing 10% (v/v) heat-inactivated new-born calf serum 
(Sijiqing, Hangzhou, China) by using ultrasound treatment 
in order to obtain MNP(Fe3O4) colloidal suspension. DNR 
conjugated with MNP(Fe3O4) were prepared by mechanical 
absorption polymerization at 4 °C for 48 h as previously 
reported.11
Cell lines and culture conditions
Human leukemia cell line K562 and its adriamycin-selected 
Pgp-overexpressing subline K562/A02 were obtained from 
the Institute of Hematology, Chinese Academy of Medical 
Sciences (Tianjin, China). Both cells were cultured in 
RPMI 1640 medium (Gibco/BRL) containing 10%(v/v) 
heat-inactivated new-born calf serum (Sijiqing),100 U/ml 
penicillin and 100 μg/ml streptomycin at 37 °C in a humidi-
fied 5% CO2 incubator. K562/A02 was cultured in the 
medium containing 1 μg/ml adriamycin for maintaining 
MDR phenotype, and maintained in drug-free medium for 
at least seven days before used.
Flow cytometric apoptosis assay
The apoptosis rates were measured using ﬂ  ow cytometric 
assay.17 Cell labeling by Annexin-V conjugated to ﬂ  uores-
cein isothiocyanate (FITC; Trevigen, Gaithersburg, MD, 
USA), which binds to phosphatidylserine exposed on the 
surface membrane of cells undergoing apoptosis. After the 
48 h incubation in the medium containing different drugs at 
37 °C, cell suspensions were washed twice with PBS and 
centrifugation at 1000r/min for 5 min. Then the cells were 
suspended in 500 μl of binding buffer (KenGen, Nanjing, 
China) and 5 μl of Annexin V-FITC (KenGen, Nanjing, 
China), incubated at room temperature for 15 min in the 
dark. The samples were measured on a ﬂ  ow cytometry with 
CellQuest software (Becton Dickinson).
DNA agarose gel electrophoresis
The typical biochemistry feature of apoptotic was detected by 
DNA gel electrophoresis.8 After treatment with the drugs, we 
used Apotosis DNA Ladder Detection Kit (KenGen, China) 
to extract DNA and then analyze DNA by electrophoresis in 
1.5% agarose gels, stained with 0.5 ug/ml ethidium bromide 
(Tiangen Biotech, Beijing, China), photographed on an ultra-
violet transilluminator. Standard molecular-weight markers 
(DNA Marker DL2000; Dongsheng, Guangzhou, China) 
were electrophoresed on each gel.International Journal of Nanomedicine 2009:4 67
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Quantitative real-time PCR (QPCR) 
analysis
After treatment with drugs, total RNA was isolated using 
Trizol reagent (Invitrogen Life Technologies, Carlsbad, 
CA, USA) according to the manufacturer’s protocol. One 
microgram of total RNA was used to generate cDNA using 
SuperScript™ II reverse transcriptase (Invitrogen Life Tech-
nologies). PCR primers were designed to amplify products 
within target and control sequences. (Primer sequences: 
P53(422bp):forward:5'-ACCCAGGTCCAGATGAAG-3'; 
reverse:5'-CACTCGGATAAGATGCTGA-3'.Caspase-
3(270bp):forward:5'-GCTATTGTGAGGCGGTTGT-
3',reverse:5'-TGTTTCCCTGAGGTTTGC-3'.GAPDH(205bp):
forward:5'-CGGATTTGGTCGTATTG-3';reverse:5'-
GAAGATGGTGATGGGATT-3') QPCR was performed 
by monitoring in real-time the increase in ﬂ  uorescence of 
SYBR green I dye (Takara, Shiga, Japan) with Rotor-Gene 
3000 (Corbett Research, Sydney, Australia). Each experi-
ment was done in triplicate. The relative gene copy number 
was calculated by the concentration-CT standard curve 
method and normalized using the average expression of 
GAPDH.19
Western blot analysis
After drug treatment, total protein was isolated and 
subjected to sodium dodecyl sulfate PAGE, and transferred 
to a polyvinylidene diﬂ  uoride membrane. The blots were 
stained with primary antibodies (1:1000–1200) overnight at 
4 °C, and then with horseradish peroxidase conjugated goat 
antirabbit or mouse secondary antibody (1:5000) for 1 h at 
room temperature. The signal was detected with an ECL 
Western Blotting Detection Kit (ZhongShan Co., Beijing, 
China). After normalization by the corresponding expression 
of β-actin, protein expression levels were determined by 
densitometry scans.19
Statistical analysis
All experiments were repeated at least three times, data were 
expressed as mean ± SD and analyzed with the Statistical 
Package for Social Science (SPSS Release 11.5; SPSS 
Inc., Chicago, IL, USA). Differences were evaluated using 
one-way ANOVA. A P value of   0.05 was considered to 
be statistically signiﬁ  cant.
Results
Enhancement of DNR-induced apoptosis 
in K562/A02 cells
The apoptotic percentage of K562/A02 cells induced 
by DNR with MNP(Fe3O4) (50 μM) or BrTet (0.5 μM) 
increased by 15.60%   ±   0.76% and 19.53%   ±   0.67%, 
respectively, compared with DNR alone (8.30% ± 0.40%) 
(p   0.05), while co-treatment of DNR with MNP(Fe3O4) 
(50 μM) and BrTet (0.5 μM) signiﬁ  cantly increased Annexin-V 
staining at 40.20% ± 1.49% (p   0.05) (Figure 1).
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Figure 1 Effects of MNP(Fe3O4) and BrTet on DNR-induced apoptosis in K562/A02 cells for 48 h. (a) control; (b) DNR 1.0 μg/ml; (c) DNR 1.0 μg/ml + MNP(Fe3O4) 50 μM; 
(d) DNR 1.0 μg/ml + BrTet 0.5 μM; (e) DNR 1.0 μg/ml + MNP(Fe3O4) 50 μM + BrTet 0.5 μM.
Abbreviations: BrTet, 5-bromotetrandrin; DNR, daunorubicin; MNP(Fe3O4), magnetic nanoparticle of Fe3O4.International Journal of Nanomedicine 2009:4 68
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DNA agarose gel electrophoresis 
demonstrated apoptosis
After co-treatment of DNR (1.0 μg/ml) with MNP(Fe3O4) 
(50 μM) and BrTet (0.5 μM), K562/A02 cells appeared on 
the DNA ladder; while a large dose of the chemotherapeutic 
agent, DNR (20.0 μg/ml), was incubated with K562/A02 
cells for 48 h, DNA agarose gel electrophoresis showed 
smear (Figure 2).
Effects of MNP(Fe3O4) and/or BrTet 
on P53 mRNA and its protein
The expression of p53 level was higher in K562/A02 
cells than in the parental sensitive K562 cells (p   0.05), 
whereas 50 μM MNP(Fe3O4), 0.5 μM BrTet or 1.0 μg/ml 
DNR did not inﬂ  uence its expression in K562/A02 cells 
(p   0.05) (Figures 3A, 3B). The level of p53 protein 
whose gene was upregulated by MNP(Fe3O4) or BrTet 
with DNR in K562/A02 cells also elevated (p   0.05). 
Furthermore, the results suggest that MNP(Fe3O4) and 
BrTet with DNR together increased the expression of p53 
protein more effectively than MNP(Fe3O4) or BrTet with 
DNR alone (p   0.05).
Effects of MNP(Fe3O4) and/or BrTet 
on caspase-3 mRNA and its protein
As shown in Figures 4A and 4B, caspase-3 was inhibited 
in Pgp-overexpressed cells after treatment with DNR. 
Nevertheless, when cells were treated with MNP(Fe3O4) 
or BrTet alone, the K562/A02 cells expressing caspase-3 
showed signiﬁ  cant resistance to these agents (p   0.05). 
However, the combination of DNR and MNP(Fe3O4) or 
BrTet yielded much more signiﬁ  cant activation of caspase-3, 
and the expression of caspase-3 mRNA and protein were 
increased in response to application of MNP(Fe3O4) and 
BrTet with DNR together (p   0.05).
Discussion
Most cytotomic agents exert their anticancer effects by 
inducing apoptotic-programmed cell death.20 The resistance 
of leukemic cells to chemotherapy-induced apoptosis remains 
the most signiﬁ  cant problem in the development of drug 
resistance and treatment failure in leukemia.3 Defects in 
the receptor- or mitochondrial-mediated apoptosis signal-
ing pathway are implicated in the development of drug 
resistance and treatment failure in leukemia.21,22 In order to 
reverse the resistance mechanism, we chose the application 
of MNP(Fe3O4) and BrTet to enhance inducing leukemia cells 
apoptosis. MNP(Fe3O4) are widely used for targeted-drug car-
riers with target-orientation and sustained-release properties.9 
In previous studies have demonstrated the synergistic effect 
of MNP(Fe3O4) with anticancer drug on the drug accumula-
tion of leukemia K562 cells may help it to inhibit the relative 
drug resistance.10 We previously reported that BrTet could 
effectively reverse P-gp-mediated MDR,16 and MNP(Fe3O4)s 
loaded with chemotherapeutic agents and chemosensitizers 
have a synergetic effect on reveral in MDR.23
In order to investigate the cytotoxicity of MNP(Fe3O4) 
and BrTet on K562/A02 cells in vitro, we investigated the 
combined effects of DNR with either MNP(Fe3O4) or BrTet 
on the apoptosis of K562/A02 cell lines (Figure 1). The com-
bination of DNR with either MNP(Fe3O4) or BrTet exerted a 
potent cytotoxic effect in K562/A02 cells, and co-treatment 
of MNP(Fe3O4) and BrTet had a distinct synergism on the 
enhancement of DNR-induced apoptosis in K562/A02 cells. 
This result showed that MNP(Fe3O4) or BrTet could enhance 
DNR-induced apoptosis in K562/A02 cells, and when used 
together, they have distinct synergism.
To check whether the effects of MNP(Fe3O4) and BrTet 
combining with a small dose chemotherapeutic agent was 
different from the effects of a large dose chemothera-
peutic agent on K562/A02 cells, we detected the typical 
MA BC D
Figure 2 DNA agarose gel electrophoresis of K562/A02 incubated with different 
drugs for 48 h.
Notes: M, Marker; A, control; B, DNR 1.0 μg/ml; C, DNR 1.0 μg/ml + MNP(Fe3O4) 
50 μM + BrTet 0.5 μM; D, DNR 20.0 μg/ml.
Abbreviations: BrTet, 5-bromotetrandrin;  DNR, daunorubicin;  MNP(Fe3O4), magnetic 
nanoparticle of Fe3O4.International Journal of Nanomedicine 2009:4 69
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biochemistry feature of apoptotic by DNA gel electropho-
resis. As shown in Figure 2, the typical apoptotic features 
appeared after co-treatment of DNR (1.0 μg/ml) with 
MNP(Fe3O4) and BrTet for 48 h, while most cells showed 
necrosis after incubated with DNR (20.0 μg/ml) for 48 h. This 
result showed that MNP(Fe3O4) or BrTet enhanced DNR-
induced apoptosis in K562/A02 cells, while 20.0 μg/ml DNR 
led cells to necrosis, which supports our assumption that the 
effects of MNP(Fe3O4) and BrTet combining with a small 
dose chemotherapeutic agent was different from the effects 
of a large dose chemotherapeutic agent on K562/A02 cell. 
This suggests that a combination of MNP(Fe3O4) and BrTet 
could be a highly feasible candidate for the development of 
a new MDR modulator.
Apoptosis in response to most DNA-damaging agents 
usually requires p53 function, which engages primarily 
the intrinsic pathway.24 Tumors that have lost p53 function 
might help circumvent resistance to conventional thera-
pies.25 Therefore, further analysis of p53 status is required 
in cancer therapies. To explore the involvement of P53 in 
the resistance to antitumor agent-induced apoptosis, we 
determined the level of P53 by real-time PCR assay and 
Western blot. Our results revealed that p53 defects are linked 
to reduced chemosensitivity. Whereas MNP(Fe3O4), BrTet, 
or DNR did not change the expression of p53 mRNA in 
K562/A02 cells, MNP(Fe3O4), and BrTet with DNR together 
increased the expression of p53 protein more effectively than 
MNP(Fe3O4) or BrTet with DNR alone (Figure 3). These 
results suggest that the augmention of P53 expression by 
DNR with MNP(Fe3O4) and BrTet possibly contributes to 
its apoptotic induction in this system. Since p53 defects are 
a major contributing factor in drug resistance and have been 
recently linked to reduced chemosensitivity, our results may 
have very important clinical implications.26
The initiation of a cascade of cysteine proteases of the 
ICE/ced3 family (caspases) plays a pivotal role in apopto-
sis.27 Caspase-3 inhibition is essential for caspase activation 
in apoptosis. Our ﬁ  ndings demonstrated that caspase-3 was 
the most likely caspase to mediate the composite-induced 
apoptosis, as shown in Figures 4A, 4B.
Conclusion
Our study demonstrates for the ﬁ  rst time that MNP(Fe3O4) 
and BrTet at subcytotoxic doses signiﬁ  cantly reversed MDR 
by synergistically enhancing DNR-induced apoptosis, and 
the distinct synergistic effect of that composite on reverse 
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MDR may owe to the regulation of various proliferative and 
antiapoptotic gene products, including P53 and caspase-3. 
Thus, it may be possible that a combination of MNP(Fe3O4) 
and BrTet may be a more sufﬁ  cient and less toxic anti-MDR 
method.
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